Wed, Sep 17, 2014, 1:56 AM EDT - U.S. Markets open in 7 hrs 34 mins

Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • adamwangwang47 adamwangwang47 Apr 30, 2013 5:44 PM Flag

    Prices for 30 capsules of Juxtapid 5mg (one month supply) is $21,013.43 with coupon

    vs Slentrol 5mg/ml (Dirlotapide by Pfizer) Solution 30 dosages for 100 bucks!!!!

    you know the rest of story when people find out Slentro does same thing as Juxtapid if not better (in dogs)

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • In particular, the risks and uncertainties include, among other factors: the risk that market acceptance of JUXTAPID may be lower than expected; the risk that prescriptions for JUXTAPID may not result in shipments of product; the risk that the actual number of patients with HoFH may be lower than our estimates; the risk that the restrictions imposed by the regulatory authorities or the side effect profile or the impact of competitive products may limit the potential of JUXTAPID; the risk that payers impose restrictions that hinder reimbursement; the risk that regulatory authorities in the E.U. or other countries outside the U.S. may not be satisfied with the efficacy or safety profile of JUXTAPID or our proposed risk management plan; the risk that we do not receive approval of JUXTAPID in the E.U. or other countries outside the U.S. on a timely basis, or at all or that regulatory authorities impose significant restrictions on approval; the risk that we do not obtain requisite pricing approvals outside the U.S; the risk that we are not able to generate the level of named patient sales in countries outside the U.S. that we expect; the risk that technical hurdles may delay initiation of future clinical trials; the risk of unexpected results in use of our commercial product or during our additional nonclinical or clinical development work with JUXTAPID; the risk of unexpected manufacturing issues affecting future supply; the risk that any of the foregoing may cause product sales revenue to be lower than we expect, or that we may incur unanticipated expenses in connection with our activities; and the other risks inherent in commercialization, drug development and the regulatory approval process.

      Sentiment: Sell

 
AEGR
32.41+0.46(+1.44%)Sep 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.